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Introduction: Acoustic cluster therapy (ACT) comprises co-administration of a
formulation containing microbubble/microdroplet clusters (PS101), together with a
regular medicinal drug (e.g., a chemotherapeutic) and local ultrasound (US) insonation
of the targeted pathological tissue (e.g., the tumor). PS101 is confined to the vascular
compartment and, when the clusters are exposed to regular diagnostic imaging US fields,
themicrodroplets undergo a phase-shift to produce bubbleswith amedian diameter of 22 µm
when unconstrained by the capillary wall. In vivo these bubbles transiently lodge in the tumor’s
microvasculature. Low frequency ultrasound (300 kHz) at a low mechanical index (MI = 0.15)
is then applied to drive oscillations of the deposited ACT bubbles to induce a range of
biomechanical effects that locally enhance extravasation, distribution, and uptake of the co-
administered drug, significantly increasing its therapeutic efficacy.
Methods: In this study we investigated the therapeutic efficacy of ACT with liposomal
doxorubicin for the treatment of triple negative breast cancer using orthotopic human
tumor xenografts (MDA-MB-231-H.luc) in athymic mice (ICR-NCr-Foxn1nu). Doxil® (6
mg/kg, i.v.) was administered at days 0 and 21, each time immediately followed by three
sequential ACT (20 ml/kg PS101) treatment procedures (n = 7–10). B-mode and
nonlinear ultrasound images acquired during the activation phase were correlated to
the therapeutic efficacy.
Results: Results show that combination with ACT induces a strong increase in the
therapeutic efficacy of Doxil®, with 63% of animals in complete, stable remission at end of
study, vs. 10% for Doxil® alone (p < 0.02). A significant positive correlation (p < 0.004) was
found between B-mode contrast enhancement during ACT activation and therapy
response. These observations indicate that ACT may also be used as a theranosticin.org February 2020 | Volume 11 | Article 751
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employed as a biomarker of therapeutic response during clinical use.Keywords: acoustic cluster therapy, microbubbles, ultrasound, drug delivery, doxorubicin, breast cancerINTRODUCTION
A prerequisite for successful therapy with a medicinal drug is that
the active substance reaches its target pathology and that toxicity to
healthy tissue and non-targeted organs is limited. Once a drug is
administrated systemically, themononuclear phagocyte system, the
vascular endothelium, the disrupted tumor blood flow, the tumor
stroma, endosomal escape, anddrug effluxpumps are a fewamonga
multitude of other biological barriers that severely restrict its
effective delivery from the vascular compartment into the tissue
of the targeted pathology (Nizzero et al., 2018). In effect: for a
number of drugs, the current, passive transvascular delivery
paradigm is inefficient, insufficient, and often results in
therapeutic agents failing to reach effective local concentrations
due to poor tumor penetration. In combination with low
therapeutic indexes, increasing the dosages is not a viable strategy
due to serious and widespread adverse effects, overall severely
limiting the clinical utility of a range of potent drugs.
While the lack of sufficient extravasation of drug to the targeted
pathology is an issueover the rangeofmedicinal therapeutic sectors,
this is in particular the case within medicinal treatment of cancers.
Regular chemotherapeutics and a range of more novel immune
therapies induce severe side effects at partially effective doses and
typically, these medicinal regimes are not terminated because the
cancer is eradicated, but because the body cannot tolerate more
treatment. The outcome is palliative benefit or life prolongation
instead of a cure. In conditions such as triple negative breast cancer
(TNBC) treated with standard of care chemotherapy, this is
unfortunately the case. Specifically, TNBC is a cancer that lacks
the expression of estrogen, progesterone, and human epidermal
growth factor 2 receptors and is strongly correlated with a poorer
outcome when compared to other breast cancer subtypes
(Bianchini et al., 2016). This is primarily due to the inherently
aggressive clinical behavior, lackof recognizedmolecular targets for
therapy, and heterogenous response to therapy. In 2018, there were
estimated to be over 2 million new cases of breast cancer making it
the second largest cancer occurrence worldwide (Bray et al., 2018).
While significant progress has been made for treatment of breast
cancer, there is still a 20% overall mortality ratio at over 620,000
patients per year. The survival impact of TNBC is even worse and
commonly referred to as the “kiss of death” (Jitariu et al., 2017) as it
is unfortunately deadly in most cases. Specifically, patients
diagnosed with TBNC have a mortality incidence from 40 to 50%
(Foulkes et al., 2010; Gonçalves et al., 2018) This clearly indicates an
important need to improve the therapeutic efficacy for the
treatment of breast cancer and even more so of TNBC.
To resolve this fundamental problem, over the past decades, a
wide range of concepts to improve the pathology-specific drug
uptake (targeted drug delivery) have been explored (Devarajan
and Jain, 2015). Within oncology, numerous drug carrierin.org 2concepts, e.g. , l iposomes, micelles, dendrimers, and
nanoparticles have been employed, either to passively make
use of the enhanced permeability and retention (EPR) effect
(Maeda et al., 2000), or in combination with surface ligands that
actively promote accumulation in tumor tissue through
biochemical affinity to specifically expressed target groups.
However, even though huge resources have been spent on
finding functional concepts for targeted drug delivery over the
last two decades, and despite promising pre-clinical results
for several of these, there has been very limited transition to
drug products and clinical practice. In truth, the objective
remains essentially unresolved in current standard-of-care
medicinal therapy.
In recent years, several concepts for ultrasound (US)
mediated drug delivery have been investigated, some with quite
encouraging results (Tsutsui et al., 2004; Martin and Dayton,
2013; Unga and Hashida, 2014). Most of these concepts explore
the use of regular US contrast microbubbles such as SonoVue®,
Optison™, or Definity®, either loaded with or co-injected with
various active ingredients. Insonation of the target pathology
containing microbubbles in vascular compartments leads to a
variety of biomechanical effects that enhance extravasation and
distribution of drug molecules to target tissue (Kooiman et al.,
2014; Lentacker et al., 2014) Co-injection of Gemcitabine and
SonoVue®, with localized US insonation for a hypothesized
enhanced drug uptake and therapeutic effect during treatment
of pancreatic cancer (PDAC) has been explored in clinical trials
with encouraging results (Dimcevski et al., 2016). A similar
approach is being investigated for treatment of glioblastoma in
humans (Carpentier et al., 2016). Whereas various drug delivery
approaches exploring the use of regular US contrast agents have
shown some promise, their effectiveness is hampered by several
issues. Being small, the magnitude of the biomechanical work
that microbubbles of 1-8µm diameter can induce is relatively
limited. In addition, as they are free flowing, they display limited
contact with the endothelial wall, further reducing the level and
range of any biomechanical effects (Kooiman et al., 2014).
Furthermore, microbubbles are typically cleared from vascular
compartments within 2–3 min and, finally, to produce sufficient
biomechanical work and effect levels, microbubbles often need a
high US intensity and as a consequence will potentially induce
inertial cavitation, with ensuing potential safety issues.
More recently, a new microbubble concept, specifically
designed to improve on the shortcomings of regular contrast
microbubbles for targeted drug delivery, has been developed:
acoustic cluster therapy (ACT) (Sontum et al., 2015; Healey et al.,
2016). ACT addresses important deficiencies of microbubble
contrast agents. In brief, ACT is defined as the co-
administration of a drug together with a dispersion of
microbubble/microdroplet clusters (PS101), followed by a two-February 2020 | Volume 11 | Article 75
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targeted by ultrasound directed at the tumor. The microbubble
in cluster acts as a vaporization seed, i.e., the US activation forces
the microbubble to oscillate which induces a liquid-to-gas phase
shift of the microdroplet component and the formation of a large
(22-mm diameter) bubbles. If the microbubble in the cluster was
not present, the microdroplet would not phase shift at low
acoustic MIs. The ACT bubbles produced by droplet
vaporisation are designed to transiently lodge at the
microvascular level of the vascular tree due to their size. The
subsequent US enhancement step induces controlled volume
oscillations that lead to enhanced local permeability of the
vasculature, allowing for improved extravasation and
distribution of drug into the tumor tissue extracellular matrix.
The ACT bubbles, being 1,000 times larger (by volume) than
regular contrast microbubbles, will induce in the range of three
orders of magnitude greater biomechanical work. When lodged
in the vascular compartment, the ACT bubbles display close
contact with the endothelial wall over significant vessel segments;
and remain for approximately 5–10 min. This allows for
prolonged insonation and biomechanical work and these
effects are induced using low intensity and low MI (<0.3) US.
The concept represents a novel approach to targeted drug
delivery that may improve significantly the efficacy of e.g.,
current chemotherapy regimens.
Previously, ACThas been explored in combinationwith a range
of drugs for treatment of several cancers, including; Abraxane®
(nab-paclitaxel) for treatment of prostate cancer (VanWamel et al.,
2016c) (Park, 2016) and paclitaxel for treatment of human
pancreatic ductal carcinoma (PDAC) (Kotopoulis et al., 2017). In
these earlier studies, a remarkable increase in the therapeutic
efficacy over drug alone was observed when combined with the
ACT procedure. In our work here we investigate the treatment of
TNBC with liposomal doxorubicin (Doxil®) using two treatments
ofACT. The therapeutic agent,Doxil, was chosen as it is considered
a different drug class to the previously evaluated chemotherapeutic
agents. Specifically, Doxil® is a liposomal nanoparticle while the
other evaluated nanoparticulate agent (Abraxane®) was a protein
bound agent. This allows us to determine to what extent ACT is
therapeutic agent agnostic. In addition, in a clinical trial using
Doxil® for treatment of metastatic breast cancer (O’Brien et al.,
2004)Doxil® showedreduced toxicity overdoxorubicinbutwithno
difference in efficacy. Here were evaluate if ACT can help improve
the therapeutic efficacy of Doxil®, potentially adding an additional
option for the treatment of metastatic breast cancer.
Furthermore, we perform a post-hoc analysis to investigate the
relationship between ultrasound imaging contrast during the
activation step and treatment efficacy as a biomarker for
prediction and monitoring of therapeutic efficacy.MATERIALS AND METHODS
Cell Line and Tumor Model
The human TNBC cells MDA-MB-231.H-luc (American Type
Culture Collection, Manassas, VA, USA, lot no. 8924081) were
grown in Leibovitz’s L-15 cell culture medium supplementedFrontiers in Pharmacology | www.frontiersin.org 3with 10% fetal bovine serum in a humidified atmosphere of 5%
CO2 at 37°C and passaged before renewal from frozen. Cells were
regularly screened for mycoplasma by PCR using in-
house primers.
Orthotopic tumors were established by injecting 3x106 cells in
100 µl Matrigel:L-15 medium (1:4) into the thoracic mammary
fat pad of 6-week old female athymic mice (ICR : NCr-Foxn1nu),
bred in-house. During xenografting, mice were anesthetized
using 2% isoflurane (Zoetis UK Ltd, UK) in oxygen. Mice were
housed in groups of five in individually ventilated cages and
allowed access to food and water ad libitum. All mice were
treated in accordance with the local Animal Welfare and Ethical
Review Board, the UK Home Office Animals Scientific
Procedures Act 1986 and with the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals in
cancer research (Workman et al., 2010).
The tumorswere allowed to grow for up to 3weeks and treatment
was initiated when tumor volumes surpassed 180 (mm)3. The
average (± SEM) starting volume was 209 ± 17 (mm)3 while the
range was 183–241 (mm)3.
Therapeutics
Clinical grade liposomal doxorubicin (DOX) (Caelyx®/Doxil®,
Janssen Pharmaceutica NV, Belgium) was stored at 2–8 °C and
freshly diluted for each treatment in 5% dextrose to a
concentration of 1.5 mg/ml and administered as an intravenous
(i.v.) bolus via a tail vein catheter. Mice were treated with DOX
doses of 6 and/or 8 mg/kg matching literature values (Working
et al., 1994).
PS101 was provided by Phoenix Solutions AS, Oslo, Norway
(Sontum et al., 2015). PS101 was prepared by reconstituting
commercially available microbubbles, Sonazoid™ (GE
He a l t h c a r e ) , w i t h a m i c r o d r op l e t emu l s i o n o f
perfluoromethylcylopentane (PFMCP, F2 Chemicals Ltd., UK)
microdroplets. The reconstituted PS101 formulation consists of a
suspension of small microbubble/microdroplet conjugates
(“clusters”) 6 x 107 clusters/ml, with a median diameter of 5 µm
(Sontum et al., 2015). The content of PFMCP, which is defined as
the active pharmaceutical ingredient (API) in PS101, is 6.8 mg/ml.
For administration of low doses, to allow for acceptable injection
volumes, PS101 was diluted in 0.9% saline prior to administration.
Treatment Protocol
Prior to each treatment anesthesia was induced by subcutaneous
(s.c.) injection of fentanyl citrate +fluanisone (Hypnorm™,
VetaPharma Ltd, Leeds, UK) and Midazolam (Hypnovel®,
Roche Products Ltd, Welwyn Garden City, UK) (0.28:10:4.5 mg/
kg). During treatments the mice were maintained on a mouse
handling table (Vevo™, Fujifilm VisualSonics Inc., Toronto) and
body temperature was controlled thermostatically, with vital signs
carefully monitored. Following treatments mice were kept in a
temperature-controlled recovery chamber until fully recovered.
Figure 1 shows a photograph (Figure 1A) and schematic
explanation (Figure 1B) of the experimental setup used to image
and treat the mice. The mice were placed in dorsal recumbency
and ultrasound gel was applied to the tumor area only. An open
polyethylene water bag was lowered until in contact with theFebruary 2020 | Volume 11 | Article 75
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treatment cycle.
A clinical US diagnostic scanner, Aplio XG ultrasound scanner
(Toshiba Medical Systems Corporation, Tochigi, Japan) combined
with a 1204BT linear array ultrasound probe was used to both
image the tumors and provide 45 s of “activation” ultrasound to
phase-shift the PS101. The clinical systemwas set to anMI of 0.33 at
a center frequency of 8 MHz at 20 fps. The clinical scanner
operating in dual imaging mode permits visualization of the
PS101 (Sonazoid component) inflow using non-linear contrast
imaging, and ACT bubble formation (Healey et al., 2016; Van
Wamel et al., 2016b) using B-mode imaging. At the end of the
activation period, ultrasound output was switched to enhancement
ultrasound applied via a custom made 300 kHz, 55 mm diameter,
single element focused transducer (Imasonic SAS, Voray-sur-
l’Ognon, France) for 5 min at an MI of 0.15 with two cycles of
excitation every 125 ms. The 300 kHz ultrasound transducer was
driven by an Analogic 2045 polynomial waveform synthesizer
(Analogic Corp, USA) amplified by a pulsed radio frequency (RF)
amplifier, BT00500 (Tomco Technologies, Australia) power
amplifier. The acoustic conditions were chosen based on a-prioriFrontiers in Pharmacology | www.frontiersin.org 4in-vitro and in-vivo experiments (Healey et al., 2016; Van Wamel
et al., 2016a)
During activation, both B-mode and contrast-mode images were
acquired for correlation with therapeutic response. The two
transducers were fixed and aligned in relation to each other so
that the imaging focus of the diagnostic array and the acoustic focus
of 300 kHz transducer coincided without interfering with the
acoustic propagation of the other transducer. Specifically, the
1204BT array was placed at 20° off the vertical axis and the 300
kHz array −40° off the vertical axis. Once the mouse was in place,
both ultrasound sources where lowered so that the acoustic foci
aligned with the center of the tumor, and the transducers’ front
surfaces were within the water bag. The acoustic pressures of the 300
kHz transducer were calibrated a priori in situ using a 200-µm
lipstick hydrophone (HGL-200, Onda Corporation, Sunnyvale, CA,
USA). The hydrophone was spot calibrated in-house at 300 kHz by
comparing to a fully calibrated needle hydrophone (1-mm,
Precision Acoustics Ltd, Dorchester, Dorset, UK). The scanner’s
on-screen values were used for the 8-MHz transducer.
For PS101 and drug delivery a catheter was assembled by
combining a winged infusion set, Surflo® 27G butterfly needleFIGURE 1 | Overview of the experimental setup and experimental timeline. Panel (A): Photograph of the experimental setup. A sample block has been positioned in
place of the animal. Panel (B): Schematic overview of the experimental setup with primary equipment labeled. Panel (C): Timeline for each treatment cycle using
acoustic cluster therapy (ACT) with Doxil®. Sham ultrasound was used for the Doxil® group.February 2020 | Volume 11 | Article 75
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polyethylene tubing, 0.4 mm i.d. (Biochrom Ltd, Cambridge, UK)
and a 27G, 0.5” hypodermic needle. It was validated a priori using
established methods (Sontum et al., 2015), that this exact injection
procedure did not affect the size distribution or activation potential
of the PS101 (Supplemental Figure 1, Supplemental Table 3). The
catheter, primed with a 0.9% saline solution, was inserted into the
lateral tail vein of the mouse and patency checked by injecting a
small volume of saline solution <5 µl. The hub of the cannula was
then filled with 0.9% saline and closed with a cap and taped to the
animal’s tail with surgical tape, which resulted in a “dead space” of
10 µl to be accounted for in subsequent injections. Just prior to each
new injection, PS101 was freshly drawn up into a 1 ml syringe and
60 µl (50 µl effective dose, plus 10 µl to allow for dead space) was
injected intravenously into the animal’s lateral tail vein via the
preplaced catheter. Three injections of PS101 followed by activation
and enhancement ultrasound were performed for each
treatment cycle.
Treatment Groups
Table 1 summarizes the treatment groups evaluated in this study.
Animals were randomized into cohorts of 8–10 mice randomly,
depending on when the tumors reached the required starting
volume. Group 1 was only PS101 followed by activation and
enhancement ultrasound. Group 2, treated with Doxil® only,
employed a reduced Doxil® dose during the second treatment
cycle to match the lower doses employed in group 3, ACT with
Doxil®, where dose was lowered during the first treatment cycle to
compensate for apparent toxicity encountered when treating the
first animals with a dose of 8mg/kg in the first treatment cycle. This
toxicity manifested as a failure to recover from the anesthetic
procedure. Hence the dose reduced to 6 mg/kg was used in the
ACT with Doxil® group and maintained for both treatment days.
Disease Development Evaluation
Animal health status was monitored daily. Tumor volumes were
obtained via caliper measurement four to five times a week up to
175 days from study start. Tumor volumes were calculated using
the ellipsoid equation 43 p(
a
4 +
b
4 )
3.
Tumor size is reported as fold increase normalized to the day
of the first treatment, i.e., day 0. Values were linearly interpolated
to single day values for graphing purposes.
Following the 3Rs of ethical research and EU directives
(Directive 2010/63/EU, 2010) a drug + US only group was notFrontiers in Pharmacology | www.frontiersin.org 5included in the study as the US exposure levels are well below
those which might cause bioeffects (Miller et al., 2008; Nelson
et al., 2009). Similarly, Sonazoid™ and saline in the absence of
US are not expected to affect tumor growth, and such groups
were not included.
Mice that showed no visible sign of the tumors at the end of
the study (day 175) were considered complete responders while
mice that were sacrificed prior to the end of the study were
considered non-responders. To minimize experimental bias and
animal suffering, a score sheet was used to determine when to
sacrifice an animal based on ulceration and tumor size
(Supplemental Table 1)
Response Assessment
Contrast Enhancement Ranking
Contrast enhancement ranking (i.e., Imaging rank) was
determined from the ultrasound images recorded during
activation following post-processing in MATLAB 2014a
(MathWorks, Massachusetts, NA, USA). Specifically, an ROI is
manually defined within the tumor core in the contrast image.
The average image intensity for frame 1 (reference image pre-
PS101 injection) and frame 300 (contrast enhanced image 15 s
after PS101 injection) and the difference between frame 1 and
frame 300, was calculated. This was repeated for all three PS101
injections on day 0 and day 21. The average of these six values
(three from each treatment day over two treatment days) was
used as the contrast metric, and determined the imaging rank.
These values were then used to produce a ranked score of
contrast enhancement by sorting them in increasing order of
contrast enhancement where a larger average contrast value is a
higher imaging rank. The attained measured values were also
used to evaluate if there were any changes in tumor perfusion
over the three sequential treatments on either of the two
treatment days.
Therapy Response Ranking
Non-responding animals, i.e., animals that were sacrificed prior
to 175 days, were ranked by survival time (shorter survival
ranked lower). Complete responders were ranked by the day
the tumor volume reached zero and stayed at zero i.e., the shorter
the time to reach zero tumor volume is a higher therapy rank.
Both the contrast enhancement and therapy response ranking
were performed by observers who were blinded to the
other ranking.
Statistical Analysis
Results for average tumor normalized volume are expressed as
mean ± standard error. Survival was compared using a Log-rank
(Mantel-Cox) test between two groups. Contrast enhancement
for comparing perfusion changes was evaluated using a simple
linear regression. Therapy and imaging rank correlation was
performed using nonparametric Pearsons correlation. A
contingency table was used to compare the number of
complete responders via Fishers exact test. A p-value less than
0.05 was considered statistically significant. All statistical analysis
was performed in Prism 8.3.0 (GraphPad Software Inc, San
Diego, CA, USA).TABLE 1 | Summary of the treatment groups: number of mice, name, and
Doxil® and acoustic cluster therapy (ACT) doses; t1 and t2 indicate the doses at
the fist (day 0) and second (day 21) treatment cycle.
Group Name Number of
animals
Treatment doses US
exposure
Doxil® (mg/kg)
t1!t2 (total)
ACT 3×(ml/
kg) t1!t2
1 PS101
+US
9 – 2.00!2.00 ✓
2 Doxil® 10 8!6 [14] – ✕
3 ACT with
Doxil®
8 6!6 [12] 2.00!2.00 ✓February 2020 | Volume 11 | Article 75
Bush et al. ACT With Doxil for TNBC TreatmentRESULTS
Tumor Growth and Development
Figure 2 shows the normalized tumor growth as a function of
time for all three groups. For ease of visualization, markers are
plotted every 4 days. Supplemental Figure 2 shows the exact
tumor volumes as a function of time.
When treated with PS101+US (Figure 2A) no therapeutic
response was observed, as expected. The tumor growth curves in
this group show a bimodal distribution; in one population 2 out
of 9 mice (22%) had a two-fold tumor growth by day 21. The
second population (78%) showed a rapid growth in the range of 2
to 6-fold growth over the first 21 days. All mice in the first
population were able to survive past 21 days in contrast to only
one mouse in the second population.
The mice treated with Doxil® (Figure 2B) showed a marked
improvement over the PS101+US group with all mice surviving
both treatment cycles. All mice showed either tumor growth
stagnation or regression over the first 21 days. Once again, there
was an inhomogeneous or bimodal distribution. One mouse
(10%) showed complete regression/response by day 21; the
remaining population (90%) showed tumor growth/recovery
within 4 weeks after the last treatment (by day 49).
Treating mice using ACT with Doxil® showed a marked
improvement over Doxil® alone (Figure 2C). Similar to both the
PS101+US and Doxil® groups, there was an inhomogeneous
population; in this instance three populations could be discerned.
By day 21, three mice (38%; mice 4, 5, and 6 c.f., Supplemental
Figure 3) showed tumor regression. Two of the three mice (mice
4 and 5 c.f., Supplemental Figure 3) stayed in complete
remission until the end of the study (first population). Three
mice (mice 6, 7, and 8 c.f., Supplemental Figure 3) showed
tumor re-growth after the second treatment cycle but presented a
delayed response resulting in complete remission starting 70 ± 2
days after the last treatment cycle (i.e., day 91) (second
population). The third population (3 mice; 38%; mice 1, 2, and
3 c.f., Supplemental Figure 3) showed continuous tumor re-
growth and did not survive the entire study period.
Figure 3 compares the perfusion of the ACT with Doxil®
tumors over the three sequential injections for both treatmentFrontiers in Pharmacology | www.frontiersin.org 6days. The linear regression was not significantly different from
zero for either of the treatment days indicating similar tumor
perfusion in all three sequential injections.
Survival
Median Overall Survival
Figure 4 shows the survival curves for the animals in the three study
groups. PS101+US resulted in a median overall survival of 21 days.
Treating with Doxil® improved overall survival significantly to 67
days (p = 0.04 vs. PS101+US) while treating using ACT with Doxil®
further improved survival (p = 0.02 vs. Doxil®, p = 0.0004 vs.
PS101+US).
Complete Responders
Both the Doxil® and ACT with Doxil® group had complete
responders, i.e., mice that showed no signs of tumor burden and
survived the complete study period of 175 days. There were no
survivors for the PS101+US group. The Doxil® group had aFIGURE 2 | Normalized tumor growth as a function of time. Each panel shows all the mice for the respective groups. Mice unable to survive the complete treatment period
are considered non-responders. Gray arrows indicate the two treatment time points. Panel (A) shows the growth curves of the mice treated with PS101+US. Panel
(B) shows the growth curves of the mice treated with Doxil®. Panel (C) shows the response of the mice treated with acoustic cluster therapy (ACT) with Doxil®.FIGURE 3 | Contrast enhancement difference 15 s post-PS101 injection for
each of the three injections for day 0 (1st treatment) and day 21 (2nd
treatment). The linear regression slope between the three sequential injections
was not significantly different from zero on day 0 (p = 0.381) or day 21 (p =
0.406).February 2020 | Volume 11 | Article 75
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group had five complete responders (63%) clearly indicating the
benefit of ACT; this difference was significant (p = 0.03).
Imaging Biomarkers of Therapeutic
Response
Figure 5 shows the correlation between the imaging and therapy
rankings. A significant positive correlation was observed (p =
0.0005, r = 0.96, Pearson r) indicating that non-linear contrast is
a predictor of therapeutic outcome when using ACT with
Doxil®. The therapy ranking of each mouse is shown in
Supplemental Table 2.
Figure 6 shows example images of a low and a high imaging
contrast ranked mouse from the ACT with Doxil® group. The
sepia toned frames are example non-linear imaging mode framesFrontiers in Pharmacology | www.frontiersin.org 7that help visualize tumor perfusion. The last row (row 3), of
images are subtractions of the pre-PS101 images (row 1) from
the 15 s post-PS101 images (row 2). This subtraction removes the
tissue harmonic component and emphasizes the Sonazoid
component. In the two illustrated examples, pre-PS101
(Figure 6, first row), the tumors (red arrows) appear as a
hypoechoic region in both B-mode and contrast-mode images
and little difference can be seen between the two. The contrast
observed is due to the tissue harmonic imaging. In the low
imaging contrast ranked mouse (Animal 2 in Supplemental
Figure 3 and Supplemental Table 2) very little enhancement
can be seen when comparing pre-PS101 injection to 15 s post-
PS101 injection, both in B-mode and non-linear contrast mode
images, i.e., the tumor remains hypoechoic (c.f., Figures 6A, B
vs. Figures 6C, D). This minimal change in image brightness can
be clearly observed in the difference frames, both for contrast-
mode and B-mode (Figures 6E, F). These frames only show the
presence of microbubbles, as the tissue harmonic contrast
component is removed via subtraction.
In the high imaging contrast ranked mouse (Animal 7 in
Supplemental Figure 3 and Supplemental Table 2) 15 s post-
PS101 injection a contrast enhancement can be observed in both
B-mode and contrast-mode resulting in the tumor being
visualized going from hypo-echoic to hyper echoic (c.f.,
Figures 6G, H vs. Figures 6I, L). The difference frames
(Figures 6K, L) clearly show the tumor noticeably bright in
both the contrast-mode and B-mode indicating that this tumor is
better perfused than the low imaging rank tumor.DISCUSSION
The use of ACT with Doxil® shows a significant improvement in
therapeutic response versus Doxil® alone, indicating the
potential of ACT to work synergistically with a liposomal
nanoparticle drug formulation. This study shows that ACT
with Doxil® can significantly improve the percentage of
complete responders and extends overall survival. In addition,
our results show that microbubble contrast enhancement of the
tumor can be used as a therapeutic biomarker predicating the
efficacy of ACT with Doxil, where more contrast enhancement
indicates a potential for better treatment.
Tumor Model
All groups in this study showed an inhomogeneous tumor
growth behavior in response to therapy, similar to that
observed in clinical practice which is also given as a key factor
behind the difficulty in successfully treating TNBC (Bianchini
et al., 2016). In clinical disease progression, metastatic spread is
also a significant reason for poor prognosis, Metastatic spread
was, however, not evaluated in this study, the reason being that
due to the high toxicity of treating with Doxil®, the addition of a
whole body imaging step to detect metastasis (such as
bioluminescence imagine) may have increased the stress on the
mice, potentially introducing early dropouts. Metastatic spread
should, however, be evaluated in future studies to determine ifFIGURE 4 | Survival curves of the three groups evaluated in the study. *p = 0.02.FIGURE 5 | Correlation between ultrasound imaging contrast rank and
therapy rank. A significant correlation between the imaging and therapy rank
was observed (p = 0.0005). The dashed gray line is the line of identity.February 2020 | Volume 11 | Article 75
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size when treating using ACT with Doxil®.
Tumor Growth Inhibition and Survival
As expected, PS101+US showed the lowest overall survival
indicating that PS101+US had little to no effect on tumor
growth. To verify this an additional control group that
received no treatment would have been ideal but was avoided
to reduce the use of animals and unnecessary stress (Directive
2010/63/EU, 2010).
Doxil® showed a significant effect with the majority of
animals having tumor regression, despite this, all but one
mouse showed tumor re-growth after the two cycles of
treatment. Transferring this to a clinical scenario, this would
indicate that a patient may need many more treatment cycles or
continuous therapy for an improved outcome.
When performing ACT with Doxil®, a synergistic effect was
observed greatly improving the therapeutic efficacy of Doxil®.
Some tumors showed rapid regression after a single treatment
cycle. One of these mice (Supplemental Figure 3, mouse 6)
showed re-growth once treatment was stopped. This single
mouse showed a delayed response, and by the end of the
treatment, no tumor could be detected. Furthermore, after a
few weeks, the majority of mice (63%) had no observable tumors
over 154 days after the last treatment. This indicated a significant
improvement in response rate and therapeutic benefit, especially
when compared to Doxil® alone. If such results could directlyFrontiers in Pharmacology | www.frontiersin.org 8translate to the clinical response, this would indicate that patients
would need fewer treatment cycles, resulting in less toxicity, with
an improved therapeutic outcome.
When comparing the survival curves, ACT with Doxil® was
significantly better than Doxil®. While the Doxil® group had a
median overall survival of 67 days, due to the high curative
efficacy of ACT with Doxil® it was not possible to calculate a
representative median survival, further emphasizing the marked
improvement over Doxil®.
PS101+US had no effect on tumor growth or survival by itself,
whereas when performed with Doxil® a significant improvement
was observed. This may imply that the mechanical action of
PS101+US is able to enhance the efficacy of Doxil® by either
increasing drug delivery or further sensitizing tissue; however,
more research should be performed to determine the
mechanisms of action behind the in-vivo synergy of ACT with
therapeutic agents.
Imaging Biomarkers of Therapeutic
Response
The correlation between the ultrasound image contrast and
therapeutic outcome indicates that the more perfused a tumor is
the better the treatment efficacy. This may indicate that higher
perfusion allowsmore PS101 and/ormore drugs to enter the tumor
volume and may be a requisite for successful ACT based therapy.
This indicates that tumor perfusion may be used as a therapeutic
biomarker or predictor of efficacy. With the need for personalizedFIGURE 6 | Ultrasound images of two acoustic cluster therapy (ACT) with Doxil® mice just before and during the activation ultrasound procedure. The left panel
(frames A–F) shows a low contrast image-ranked tumor and the right panel (frames G–L) shows a high contrast image-ranked tumor. The first row (frames A, B, G,
and H) are prior to PS101 injection. The second row (frames C, D, I, and J) are 15 s post-PS101 injection, while activation ultrasound is being applied. The third row
(frames E, F, K, and L) shows the difference between first and second row. A pronounced difference is observable between the low image-ranked tumor and high
image-ranked tumor in both the contrast-mode and B-mode images.February 2020 | Volume 11 | Article 75
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this points towardACTbased therapies being an optimal choice for
the next generation of therapeutics (Tran et al., 2018).
Comparing clinical findings for various breast cancer types,
tumours of patients with TNBC show the largest amount of
microbubble perfusion when using contrast enhanced
ultrasound indicating the potential for ACT in treating patients
with TNBC (Masumoto et al., 2016).
The primary limitations of this data set are the limited
number of animals (n = 8), the limited proportion of the
volume of each tumour (only a single imaging plane), that
were studied. Future work should aim to determine the
sensitivity and specificity of such imaging biomarkers using
sufficient animals for adequately powered estimates, as well as
characterize PS101 uptake in the entire tumor volume.
Limitations and Future Work
While this study provides strong evidence that ACT with Doxil®
can enhance the therapeutic efficacy versus Doxil® alone, there are
several limitations that should be addressed in future studies.
The underlying mechanisms of this enhanced therapeutic effect
were not evaluated within this study.While it may be assumed that
this is due to increased delivery of the chemotherapeutic agent or
changing the release profile this has not been directly provenwithin
this model. Nevertheless, previous work has demonstrated that
ACT is able to enhance the deposition of large dyes molecules (2.5
nm diameter) into tissue in vivo (Van Wamel et al., 2016b)
indicating that this may be a contributory mechanism. The
mechanism underlying the delayed therapeutic response is,
however, as yet not clearly understood.
In this study, three sequential injections of PS101 were
performed, spaced only 6 min apart. As the in-vivo lifetime of
PS101 can be longer than this time period, this allows the
assumption that each subsequent injection may have residual
un-activated PS101, increasing the attenuation with each
injection. Consequently, further work should be performed to
optimize the PS101 dose and acoustic conditions to account for
this potential phenomenon.
Vascular shut down due to ultrasound and microbubble
treatment has been reported at high mechanical indices [e.g.,
MI 1.6 (Goertz et al., 2012)]. In our study here, no vascular
shutdown was observed either after any of the three PS101
injections or on any of the treatment days. This indicates that
vascular shut down may not be part of the mechanisms of action
of ACT. This also supports the use of the three back-to-back
injection of PS101 as the clusters will still be able to perfuse
through the tumor.
To verify that the improved efficacy seen with ACT, over
Doxil® alone, is due to the large activated ACT bubbles, not just
the Sonazoid component, future work should include a Sonazoid
control group.
Although the off-target toxicity/safety was not directly
evaluated in this study it remains a key point of interest for
such a targeted drug delivery mechanism. Extensive studies have
been performed in several species and determined that there are
minimal toxicities induced by ACT and, when they exist, they are
transient and recoverable (Myhre et al., 2016; Bush et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 9While ultrasound and microbubbles have been used to
enhance the treatment efficacy for TNBC (Bai et al., 2019; Jing
et al., 2019; Song et al., 2019), this has not been previously
explored with ACT and to our current knowledge, no other study
has shown such a marked improvement in tumor regression,
significantly improved survival and number of complete
responders, and theranostic potential.CONCLUSION
ACT significantly improves the response to treatment with Doxil®
of human triple negative breast cancer in mice, as measured by
tumor size and overall survival, with 63% of tumors entering
complete regression with ACT versus 10% with Doxil® alone.
ACT has potential theranostic attributes and ultrasound contrast
enhancement during or before ACT treatmentmay be employed as
a biomarker of therapeutic response and, potentially, for patient
stratification in clinical management.DATA AVAILABILITY STATEMENT
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